Search PubMedSearch

PubMed · 9716292

Prostatitis: US perspective.

Abstract

The diagnosis and management of prostatitis syndromes is a challenge to the clinician. Careful history and examination of the prostate fluid and quantitative segmented bacteriologic cultures will lead to proper categorization into the recognized forms of the prostatitis syndrome. Antimicrobial therapy is effective in the majority of men with acute and chronic bacterial prostatitis (CBP). Fluoroquinolone agents appear to have an increasingly important role in this regard, although a randomized, prospective, double-blind study is still lacking. Alpha-1-selective blocking agents may relieve symptomatology of chronic pelvis pain syndrome (CPPS). Other non-prostatic sources of voiding symptoms should be sought and ruled out, especially malignancy or inflammatory disorders.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A J Schaeffer. 1998. Prostatitis: US perspective.. https://doi.org/10.1016/s0924-8579(98)00029-6

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Role of leukocyte influx in tissue prostaglandin H synthase-2 overexpression induced by phorbol ester and arachidonic acid in skin.

The accumulation of neutrophils and mononuclear cells is a characteristic feature of 12-O-tetradecanoylphorbol 13-acetate (TPA)-induced ear edema. This cell influx was accompanied by the enhancement of eicosanoid tissue levels and prostaglandin H synthase-2 (PGHS-2) overexpression. Sialidase treatment, which affects the structure of selectins and inhibits leukocyte influx, significantly reduced eicosanoid and PGHS-2 levels and edema. In contrast, skin PGHS-2 overexpression induced by arachidonic acid (AA) application was not affected by sialidase treatment. These results suggest that PGHS-2 overexpression induced by TPA could be induced by AA and/or AA metabolite release by leukocyte infiltrated during the inflammatory process.

Acute Disease

Phase I study of (131)I-anti-CD45 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome.

Delivery of targeted hematopoietic irradiation using radiolabeled monoclonal antibody may improve the outcome of marrow transplantation for advanced acute leukemia by decreasing relapse without increasing toxicity. We conducted a phase I study that examined the biodistribution of (131)I-labeled anti-CD45 antibody and determined the toxicity of escalating doses of targeted radiation combined with 120 mg/kg cyclophosphamide (CY) and 12 Gy total body irradiation (TBI) followed by HLA-matched related allogeneic or autologous transplant. Forty-four patients with advanced acute leukemia or myelodysplasia received a biodistribution dose of 0.5 mg/kg (131)I-BC8 (murine anti-CD45) antibody. The mean +/- SEM estimated radiation absorbed dose (centigray per millicurie of (131)I) delivered to bone marrow and spleen was 6.5 +/- 0.5 and 13.5 +/- 1.3, respectively, with liver, lung, kidney, and total body receiving lower amounts of 2.8 +/- 0.2, 1.8 +/- 0.1, 0.6 +/- 0.04, and 0.4 +/- 0.02, respectively. Thirty-seven patients (84%) had favorable biodistribution of antibody, with a higher estimated radiation absorbed dose to marrow and spleen than to normal organs. Thirty-four patients received a therapeutic dose of (131)I-antibody labeled with 76 to 612 mCi (131)I to deliver estimated radiation absorbed doses to liver (normal organ receiving the highest dose) of 3.5 Gy (level 1) to 12.25 Gy (level 6) in addition to CY and TBI. The maximum tolerated dose was level 5 (delivering 10.5 Gy to liver), with grade III/IV mucositis in 2 of 2 patients treated at level 6. Of 25 treated patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS), 7 survive disease-free 15 to 89 months (median, 65 months) posttransplant. Of 9 treated patients with acute lymphoblastic leukemia (ALL), 3 survive disease-free 19, 54, and 66 months posttransplant. We conclude that (131)I-anti-CD45 antibody can safely deliver substantial supplemental doses of radiation to bone marrow (approximately 24 Gy) and spleen (approximately 50 Gy) when combined with conventional CY/TBI.

Acute Disease